Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,534 INR | +0.96% |
|
+1.63% | +13.11% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.11% | 1.39B | - | ||
+25.40% | 45.35B | B- | ||
+38.38% | 24.34B | B+ | ||
+26.53% | 16.51B | - | ||
+21.19% | 14.6B | B+ | ||
+71.91% | 14.27B | B | ||
-0.05% | 6.79B | - | - | |
-11.63% | 6.57B | B+ | ||
+15.08% | 5.76B | B+ | ||
-8.87% | 5.73B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CAPLIPOINT Stock
- CAPLIPOINT Stock
- Ratings Caplin Point Laboratories Limited